Novartis Ag (NVS) EBT Margin (2016 - 2025)
Historic EBT Margin for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to 388.65%.
- Novartis Ag's EBT Margin rose 3636700.0% to 388.65% in Q4 2025 from the same period last year, while for Dec 2025 it was 497.63%, marking a year-over-year increase of 4705200.0%. This contributed to the annual value of 29.99% for FY2025, which is 28800.0% up from last year.
- Novartis Ag's EBT Margin amounted to 388.65% in Q4 2025, which was up 3636700.0% from 574.79% recorded in Q3 2025.
- Novartis Ag's EBT Margin's 5-year high stood at 670.78% during Q1 2025, with a 5-year trough of 13.17% in Q3 2023.
- Over the past 5 years, Novartis Ag's median EBT Margin value was 24.88% (recorded in 2021), while the average stood at 125.67%.
- As far as peak fluctuations go, Novartis Ag's EBT Margin crashed by -1133000bps in 2022, and later skyrocketed by 6443200bps in 2025.
- Over the past 5 years, Novartis Ag's EBT Margin (Quarter) stood at 128.14% in 2021, then tumbled by -88bps to 14.84% in 2022, then soared by 40bps to 20.81% in 2023, then increased by 20bps to 24.98% in 2024, then skyrocketed by 1456bps to 388.65% in 2025.
- Its last three reported values are 388.65% in Q4 2025, 574.79% for Q3 2025, and 423.06% during Q2 2025.